Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05382637 · ClinicalTrials.gov registry record · Phase 2
Growth Hormone in a Patient With a Dominant-Negative GHR Mutation
A Phase 2 study of Growth Disorders, sponsored by Children's National Research Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
- 1
- Study location
NCT05382637: Active Phase 2 study of Growth Disorders, sponsored by Children's National Research Institute.
NCT05382637 is a Phase 2 study of Growth Disorders that is active but no longer recruiting, run by Children's National Research Institute. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05382637, a Phase 2 study of Growth Disorders, is active but no longer recruiting, sponsored by Children's National Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective interventional study designed for a single patient with a dominant-negative mutation in the growth hormone receptor gene (GHR) which results in increased levels of growth hormone binding protein (GHBP). The patient will receive escalating doses of growth hormone titrated to achieve an insulin like growth factor-1 level above the mean and then growth response to therapy will be monitored.
Primary Outcome
Dose of growth hormone required in mg/kg/day to achieve an IGF-1 level above the mean
Conditions Studied
Interventions
- DRUG Somatropin
Study Locations (1)
District of Columbia
- Children's National Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2022-08-26 |
| Est. Completion | 2028-09-01 |
| Phase | Phase 2 |
What the registry record for NCT05382637 still lists
NCT05382637 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Growth Disorders appearing as the primary indexed condition, and to 1 intervention - of which Somatropin is the first listed.
NCT05382637 reports a single indexed study location in District of Columbia.
Frequently Asked Questions
What is clinical trial NCT05382637 about?
NCT05382637 is a clinical study titled "Growth Hormone in a Patient With a Dominant-Negative GHR Mutation". This is a prospective interventional study designed for a single patient with a dominant-negative mutation in the growth hormone receptor gene (GHR) which results in increased levels of growth hormone binding protein (GHBP). The patient will receive escalating doses of growth hormone titrated to ach...
What is the current status of trial NCT05382637?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2022-08-26. Estimated completion is 2028-09-01.
What conditions does trial NCT05382637 study?
This clinical trial studies the following conditions: Growth Disorders.
What interventions are being tested in trial NCT05382637?
The interventions under investigation include: Somatropin (DRUG).
Who is sponsoring clinical trial NCT05382637?
This trial is sponsored by Children's National Research Institute, which has 92 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05382637 being conducted?
This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Growth Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05382637's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI